Absolute Return Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Absolute Return Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-4,496	Closed	-$307K	–	1233
2014 Q1	$307K	Buy	+4,496	New	+$331K	﹤0.01%	958
2013 Q3	–	Sell	-5,519	Closed	-$308K	–	637
2013 Q2	$308K	Buy	+5,519	New	+$344K	﹤0.01%	649

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Absolute Return Capital's BMRN Position: Q2 2014 in Review

Absolute Return Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2014, closing a stake of 4,496 shares — an estimated $307K sold.

Absolute Return Capital first reported a position in BMRN in Q2 2013 and held it in 2 quarters. The position peaked at $308K in Q2 2013. 321 funds tracked by Wall St. Rank hold BMRN as of Q2 2014.

Absolute Return Capital reported no remaining BioMarin Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
Absolute Return Capital sold 4,496 BioMarin Pharmaceuticals shares in Q2 2014, an estimated $307K.
Absolute Return Capital first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 2 quarters.
Absolute Return Capital's BioMarin Pharmaceuticals position peaked at $308K in Q2 2013.
321 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2014.

Based on Absolute Return Capital's 13F filing for Q2 2014, filed 14 Aug 2014.